Virus therapy fights Hard-to-Treat colorectal cancer in early trial
NCT ID NCT05733611
First seen Feb 02, 2026 · Last updated May 23, 2026 · Updated 16 times
Summary
This study tested a new treatment for advanced colorectal cancer that has stopped responding to standard chemotherapy. The treatment combines a virus that attacks cancer cells (oncolytic immunotherapy) with two approved drugs, atezolizumab and bevacizumab. The trial enrolled only 5 adults whose cancer was a specific type (MSS/pMMR) and was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY METASTATIC COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
USC Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
University of Washington Seattle Cancer Care Alliance
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.